Home Business Heat Biologics stock more than doubles after ‘positive’ trial data of its lung cancer treatment

Heat Biologics stock more than doubles after ‘positive’ trial data of its lung cancer treatment

Nio's stock jumps into record territory after unveiling of ET7 luxury sedan

Shares of Heat Biologics Inc.
HTBX,
+76.58%
more than doubled in very active trading Tuesday, after the biopharmaceutical company focused on modulating the immune system reported “positive” interim data from a Phase 2 trial of its lung cancer treatment. The stock soared 115% toward a seven-month high ahead of the open on volume of 15.1 million shares, which compares with the full-day average of 1.4 million shares over the past 30 days. The company said a trial of its HS-110, in combination with Britol-Myers Squibb Co.’s OPDIVO in advanced non-small cell lung cancer (NSCLC). showed “substantial” survival benefit, with a median progression free survival of 1.8 months and a median overall survival of 24.6 months. “Our data suggests that addition of HS-110 to a checkpoint inhibitor has the potential to improve survival benefit for checkpoint inhibitor naïve NSCLC patients,” the company said. The stock has rallied 16.1% over the past three months through Monday, while the iShares Nasdaq Biotechnology ETF
IBB,
-0.01%
has advanced 25.4% and the S&P 500
SPX,
-0.14%
has gained 10.3%.

This article is auto-generated by Algorithm Source: www.marketwatch.com

Related Posts

0